RecruitingPhase 1Phase 2NCT05978284

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

A Phase 1/2 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Enrollment

54 participants

Start Date

Oct 27, 2023

Study Type

INTERVENTIONAL

Conditions

Small Cell Lung Cancer Neuroendocrine Carcinoma

Summary

This is a multi-center, open-label, Phase Ⅰ/Ⅱ clinical study of ZG006 for the treatment of participants with small cell lung cancer or neuroendocrine carcinoma who had no standard treatment available, or were intolerant to standard treatment.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called ZG006 for people with small cell lung cancer (SCLC) or neuroendocrine carcinoma (NEC) — aggressive cancers that often stop responding to standard treatments. ZG006 targets a protein called DLL3 that is found on the surface of these cancer cells. **You may be eligible if...** - You are 18–75 years old - You have confirmed small cell lung cancer or neuroendocrine carcinoma - Standard treatments are no longer working or are not tolerable for you - Your cancer tissue is available for testing for DLL3 protein - You are in reasonably good health (ECOG performance status 0–1) - You are expected to survive at least 3 months **You may NOT be eligible if...** - You have not recovered from side effects of previous treatment - You do not have measurable disease on imaging - You have serious organ dysfunction Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.